Hasil Pencarian

Hasil Pencarian  ::  Simpan CSV :: Kembali

Hasil Pencarian

Ditemukan 2 dokumen yang sesuai dengan query
cover
Emma Mardliyah Hidayat
"Infeksi parasit masih merupakan masalah di dunia, terutama di daerah endemis. Adanya pandemi menyebabkan kemungkinan terjadinya misdiagnosed ataupun late diagnosed dari infeksi parasit karena gejala klinis yang mirip. Penelitian ini bertujuan untuk mengetahui penegakan diagnosis dan tatalaksana infeksi parasit pada pasien dengan koinfeksi COVID-19. Metode yang dilakukan adalah dengan tinjauan pustaka sistematis pada berbagai laporan kasus yang dipublikasikan. Penelusuran artikel dilakukan sesuai dengan alur pada diagram Prisma secara online melalui PubMed, Google Scholar, Hindawi, Cochrane library, Science direct, DOAJ, Public Library of Science (PLoS). Kata kunci yang digunakan yaitu parasite infection, COVID-19, parasite coinfection covid, intestinal parasite, helminthiasis, protozoa infection, ascariasis, trichuriasis, hookworm, strongyloidiasis, filariasis, schistosomiasis, amebiasis, giardiasis, malaria, typanosomiasis, leishmaniasis. dengan menggunakan quoatation mark “ “ dan Boolean operator “OR” “AND”. Hasil penelusuran didapatkan 700 artikel kemudian dilakukan penapisan dan telaah sehingga didapatkan 14 artikel yang sesuai untuk dianalisis. Dari 14 artikel tersebut didapatkan 17 kasus infeksi parasit, yaitu 2 kasus strongyloidiasis, 1 kasus filariasis, 11 kasus malaria, 2 kasus chagas disease, dan 1 kasus visceral leismahniasis. Penegakan diagnosis infeksi parasit pada pasien koinfeksi COVID-19 58,8% terlambat dilakukan. Tatalaksana infeksi parasit sudah sesuai dengan diagnosis, tetapi perlu diperhatikan adanya interaksi obat. Pemeriksaan diagnostik untuk infeksi parasit pada koinfeksi COVID-19 hendaknya dilakukan secara dini agar penyakit dapat teratasi dengan baik.

A parasitic infection has always been a global issue, especially in an endemic area. The occurrence of pandemic increases the possibility of either misdiagnosed or late-diagnosed of parasitic infection due to the similarity of clinical manifestation. This study was aimed at determining the diagnosis and management of parasitic infection in COVID-19 co- infection patients. The method used in this study was a systematic literature review of various published case reports. Article searches were executed based on the flow on the Prism diagram online through PubMed, Google Scholar, Hindawi, Cochrane library, Science direct, DOAJ, Public Library of Science (PLoS). The keywords used were parasite infection, COVID-19, parasite co-infection covid, intestinal parasite, helminthiasis, protozoa infection, ascariasis, trichuriasis, hookworm, strongyloidiasis, filariasis, schistosomiasis, amebiasis, giardiasis, malaria, trypanosomiasis, leishmaniasis, applying the quotation mark “ ” and the Boolean operator “OR” “AND”. The search results gathered 700 articles which were filtered and analyzed that narrowed to 14 journals suitable for the analysis. Out of these 14 journals, 17 cases of parasitic infection were found, namely 2 cases of strongyloidiasis, 1 case of filariasis, 11 cases of malaria, 2 cases of Chagas disease, and 1 case of visceral leishmaniasis. About 58.8% of patients coinfected with COVID-19 were diagnosed late. The management of parasitic infection has been done in accordance with the diagnosis, but drug interaction must be considered. Early diagnostic examination for patients coinfected with COVID-19 is highly suggested to ensure that the disease is treated well."
Lengkap +
Jakarta: Fakultas Kedokteran Universitas Indonesia, 2021
SP-pdf
UI - Tugas Akhir  Universitas Indonesia Library
cover
Canda Insyira Tamarahen
"Ivermectin merupakan obat yang telah disetujui FDA untuk digunakan pada Strongyloidiasis dan Onchocerciasis, yaitu dua kondisi yang disebabkan oleh cacing parasit. Namun ivermectin banyak disalahgunakan sebagai obat COVID-19 yang sebenarnya membutuhkan dosis berkali lipat agar konsentrasi plasma yang dibutuhkan untuk efikasi antivirus tercapai. Oleh karena itu, perlu dilakukan uji profil farmakokinetika untuk mengetahui keamanan, efikasi, serta toksisitas suatu obat. Pengujian ini dilakukan dengan menganalisis kadar ivermectin pada plasma 6 orang subjek Indonesia sehat yang telah mengonsumsi tablet ivermectin 12 mg secara oral menggunakan Kromatografi Cair Kinerja Ultra Tinggi Tandem Spektrometri Massa (KCKUT-SM/SM). Pengambilan darah subjek dilakukan sebanyak 16 titik pada beberapa interval waktu hingga jam ke-72. Kondisi kromatografi yang digunakan adalah kolom Acquity UPLC BEH C18 (2,1 x 100 mm x 1,7 µm); suhu kolom 40oC; fase gerak amonium format 5 mM pH 3 – asetonitril dengan perbandingan 10:90; laju alir 0,2 mL/menit; dan doramectin sebagai baku dalam. Profil farmakokinetika dalam sampel plasma menghasilkan; AUC0-t 518,43 ± 71,89 ng/mL; AUC0- 582,92 ± 114,28 ng/mL; Cmaks 47,79 – 53,31 ng/mL; tmaks 4,50 ± 0,00 jam; dan t½ 23,15 ± 6,81 jam. Berdasarkan penelitian sebelumnya, Cmaks in vitro yang dibutuhkan untuk mematikan virus COVID-19 yaitu sebesar ± 5 µg/mL, apabila dibandingkan dengan Cmaks yang diperoleh pada penelitian ini, memperoleh kesimpulan bahwa konsentrasi untuk mematikan virus COVID-19 tidak tercapai.

Ivermectin is a drug approved by FDA that used for Strongyloidiasis and Onchocerciasis, two conditions caused by parasitic worms. However, ivermectin is widely misused as a COVID-19 drug which requires multiple doses to achieve the plasma concentration required for antiviral efficacy. Therefore, it is necessary to test the pharmacokinetic profile to determine the safety, efficacy, and toxicity of the drug. This test was done by analizing the ivermectin levels in the plasma of 6 healthy Indonesian subjects who had taken 12 mg of ivermectin tablet orally by using Ultra High Performance Liquid Chromatography Tandem – Mass Spectrmetry (UHPLC-MS/MS). Subjects’ blood sampling was collected as many as 16 points at several time intervals up to 72 hours. The chromatographic conditions used was Acquity UPLC BEH C18 column (2.1 x 100 mm x 1.7 µm); 40oC column temperature; mobile phase consists of ammonium formate 5 mM pH 3 – acetonitrile with 10:90 comparison; 0,2 mL/minute flow rate; and doramectin as an internal standard. The pharmacokinetic profile in plasma results were; AUC0-t was 518,43 ± 71,89 ng/mL; AUC0- was 582,92 ± 114,28 ng/mL; Cmax ranged from 47,79 to 53,31 ng/mL; tmax was 4,50 ± 0,00 hours; and t½ was 23,15 ± 6,81 hours. Based on previous research, the in vitro Cmax required to kill the COVID-19 virus is ± 5 g/mL, when compared with the Cmax obtained in this study, it is concluded that the concentration to kill the COVID-19 virus was not achieved."
Lengkap +
Depok: Fakultas Farmasi Universitas Indonesia, 2022
S-pdf
UI - Skripsi Membership  Universitas Indonesia Library